Cargando…
Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
BACKGROUND AND OBJECTIVE: Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson’s disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa–carbidopa intestinal gel (LCIG) provides individualized continuous levodopa–carbidop...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559582/ https://www.ncbi.nlm.nih.gov/pubmed/25875940 http://dx.doi.org/10.1007/s40262-015-0265-3 |
_version_ | 1782388798493032448 |
---|---|
author | Othman, Ahmed A. Chatamra, Krai Mohamed, Mohamed-Eslam F. Dutta, Sandeep Benesh, Janet Yanagawa, Masayoshi Nagai, Masahiro |
author_facet | Othman, Ahmed A. Chatamra, Krai Mohamed, Mohamed-Eslam F. Dutta, Sandeep Benesh, Janet Yanagawa, Masayoshi Nagai, Masahiro |
author_sort | Othman, Ahmed A. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson’s disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa–carbidopa intestinal gel (LCIG) provides individualized continuous levodopa–carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and efficacy of LCIG relative to LC-oral in Japanese subjects with advanced PD. METHODS: Subjects with advanced PD were converted from their anti-PD medications to individually optimized doses of LC-oral (10:1 levodopa:carbidopa ratio) for 28 days (baseline; period 1) followed by switching to intrajejunal infusion of LCIG (4:1 ratio) for 21 days (period 2). Pharmacokinetics, adverse events (AEs), and efficacy were assessed. RESULTS: Eight patients were enrolled. Six received LCIG and four reported at least one AE [most common: fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. The degree of fluctuation and intra-subject variability of levodopa plasma concentrations were 5.5- and 4-fold lower, respectively, with LCIG than with LC-oral. Levodopa bioavailability was 99 % for LCIG relative to LC-oral. Compared with baseline, LCIG decreased “Off” time (2.68 h, P = 0.002) and increased “On” time without troublesome dyskinesia (2.35 h, P = 0.006) in the PD Diary(©). With the small sample size, no statistically significant changes were seen on other efficacy endpoints. CONCLUSIONS: In Japanese subjects with advanced PD, LCIG resulted in an improved pharmacokinetic profile that appeared to be associated with reduced motor complications compared with LC-oral. These results extend previous findings in mainly Caucasian populations. |
format | Online Article Text |
id | pubmed-4559582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-45595822015-09-10 Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety Othman, Ahmed A. Chatamra, Krai Mohamed, Mohamed-Eslam F. Dutta, Sandeep Benesh, Janet Yanagawa, Masayoshi Nagai, Masahiro Clin Pharmacokinet Original Research Article BACKGROUND AND OBJECTIVE: Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson’s disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa–carbidopa intestinal gel (LCIG) provides individualized continuous levodopa–carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and efficacy of LCIG relative to LC-oral in Japanese subjects with advanced PD. METHODS: Subjects with advanced PD were converted from their anti-PD medications to individually optimized doses of LC-oral (10:1 levodopa:carbidopa ratio) for 28 days (baseline; period 1) followed by switching to intrajejunal infusion of LCIG (4:1 ratio) for 21 days (period 2). Pharmacokinetics, adverse events (AEs), and efficacy were assessed. RESULTS: Eight patients were enrolled. Six received LCIG and four reported at least one AE [most common: fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. The degree of fluctuation and intra-subject variability of levodopa plasma concentrations were 5.5- and 4-fold lower, respectively, with LCIG than with LC-oral. Levodopa bioavailability was 99 % for LCIG relative to LC-oral. Compared with baseline, LCIG decreased “Off” time (2.68 h, P = 0.002) and increased “On” time without troublesome dyskinesia (2.35 h, P = 0.006) in the PD Diary(©). With the small sample size, no statistically significant changes were seen on other efficacy endpoints. CONCLUSIONS: In Japanese subjects with advanced PD, LCIG resulted in an improved pharmacokinetic profile that appeared to be associated with reduced motor complications compared with LC-oral. These results extend previous findings in mainly Caucasian populations. Springer International Publishing 2015-04-15 2015 /pmc/articles/PMC4559582/ /pubmed/25875940 http://dx.doi.org/10.1007/s40262-015-0265-3 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Article Othman, Ahmed A. Chatamra, Krai Mohamed, Mohamed-Eslam F. Dutta, Sandeep Benesh, Janet Yanagawa, Masayoshi Nagai, Masahiro Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety |
title | Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety |
title_full | Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety |
title_fullStr | Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety |
title_full_unstemmed | Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety |
title_short | Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety |
title_sort | jejunal infusion of levodopa–carbidopa intestinal gel versus oral administration of levodopa–carbidopa tablets in japanese subjects with advanced parkinson’s disease: pharmacokinetics and pilot efficacy and safety |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559582/ https://www.ncbi.nlm.nih.gov/pubmed/25875940 http://dx.doi.org/10.1007/s40262-015-0265-3 |
work_keys_str_mv | AT othmanahmeda jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety AT chatamrakrai jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety AT mohamedmohamedeslamf jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety AT duttasandeep jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety AT beneshjanet jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety AT yanagawamasayoshi jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety AT nagaimasahiro jejunalinfusionoflevodopacarbidopaintestinalgelversusoraladministrationoflevodopacarbidopatabletsinjapanesesubjectswithadvancedparkinsonsdiseasepharmacokineticsandpilotefficacyandsafety |